$1.98
▲ +$0.03
(+1.54%)
Vol 320K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$43.4M
ROE
-126.9%
Margin
-2381.8%
D/E
5.93
Beta
1.32
52W
$1–$7
Wall Street Consensus
12 analysts · Apr 20264
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
91.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 0.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.08 | $-0.09 | $-0.01 |
| Sep 2025 | $-0.10 | $-0.11 | $-0.01 |
| Jun 2025 | $-0.37 | $-0.49 | $-0.12 |
| Mar 2025 | $-0.33 | $-0.49 | $-0.16 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $200K | — | $200K | $100K | — |
| Net Income | — | -$4.4M | -$4.9M | -$5.2M | -$5.7M | -$9.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -126.9% | -130.5% | -126.9% | -126.9% | -126.9% | -126.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -2581.5% | -3237.9% | -2381.8% | -2381.8% | -2381.8% | -2381.8% |
| Gross Margin | — | 52.1% | 52.1% | 52.1% | 52.1% | 52.1% |
| D/E Ratio | 5.93 | 9.35 | 5.93 | 5.93 | 5.93 | 5.93 |
| Current Ratio | 1.59 | 1.12 | 1.59 | 1.59 | 1.59 | 1.59 |
Key Ratios
ROA (TTM)
-83.1%
P/S (TTM)
108.50
P/B
0.7
EPS (TTM)
$-1.79
CF/Share
$-1.62
Rev Growth 3Y
-40.3%
52W High
$6.89
52W Low
$0.56
$0.56
52-Week Range
$6.89
Financial Health
Free Cash Flow
-$5.8M
Net Debt
-$26.2M
Cash
$28.7M
Total Debt
$2.5M
As of Dec 31, 2025
How does IBIO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IBIO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
108.5
▲
744%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.7
▼
73%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IBIO profitability vs Biotechnology peers
ROE
-126.9%
▼
89%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-2381.8%
▼
731%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
52.1%
▼
34%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-83.1%
▼
78%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
IBIO financial health vs Biotechnology peers
D/E ratio
5.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.6
▼
64%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.3
▲
36%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
IBIO fundamentals radar
IBIO
Peer median
Industry
IBIO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IBIO vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BANJAK MARC
Officer · Mar 26
13934 shs
BRENNER MARTIN
Chief Executive Officer · Mar 19
12336 shs
DURAN FELIPE
Chief Financial Officer · Mar 19
24835 shs
Last 90 days
Top Holders
Top 5: 27.03%EcoR1 Capital, LLC
6.45%
$4.0M
Affinity Asset Advisors, Llc
5.96%
$3.7M
Logos Global Management LP
5.79%
$3.6M
Frazier Life Sciences Manag…
5.66%
$3.5M
Balyasny Asset Management LP
3.17%
$2.0M
As of Dec 31, 2025
Latest News
No related news yet